Studies Suggest Delaying Infant Hepatitis B Vaccine Could Increase Infections

New research published in JAMA Pediatrics indicates that a recent recommendation to delay the first hepatitis B shot for infants born to mothers testing negative for the virus may lead to hundreds of additional infections. This guidance, issued in December 2025, contrasts with long-standing recommendations from major medical societies for a universal birth dose. The studies also project an increase in liver cancer cases, deaths, and healthcare costs.

Context

Historically, major medical societies have advocated for a universal birth dose of the hepatitis B vaccine to protect infants from infection. In December 2025, new guidance suggested delaying this vaccination for infants born to mothers who test negative for the virus. This shift in recommendations has raised concerns among healthcare professionals and researchers.

Why it matters

The recommendation to delay the hepatitis B vaccine for infants could have significant public health implications. Increased infections may lead to higher rates of liver cancer and associated healthcare costs. Understanding the impact of this policy is crucial for safeguarding infant health.

Implications

If the delayed vaccination policy remains in place, it could lead to a rise in hepatitis B infections among infants. This may result in increased cases of liver cancer and higher healthcare costs for families and the healthcare system. Vulnerable populations, particularly infants, could be disproportionately affected by this change in vaccination strategy.

What to watch

Health authorities and medical organizations may respond to the new research findings by reevaluating vaccination guidelines. Monitoring infection rates and liver cancer cases in the coming years will be critical. Public health campaigns may emerge to address the potential rise in hepatitis B infections.